VOYA Investment Management
JBIO

VOYA Investment Management’s Jade Biosciences JBIO Stock Holding History

VOYA Investment Management’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,876
Closed -$137K – 2737
2024
Q3 		$137K Buy
+1,876
New +$121K ﹤0.01% 2588

Other funds holding JBIO

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
AI
Allostery Investments Stamford, Connecticut $7.85M AUM

VOYA Investment Management's JBIO Position: Q4 2024 in Review

VOYA Investment Management sold out of Jade Biosciences (JBIO) in Q4 2024, closing a stake of 1,876 shares — an estimated $137K sold.

VOYA Investment Management first reported a position in JBIO in Q3 2024 and held it in 1 quarter. The position peaked at $137K in Q3 2024. 78 funds tracked by Wall St. Rank hold JBIO as of Q4 2024.

  • VOYA Investment Management reported no remaining Jade Biosciences position as of Q4 2024 after selling out during the quarter.
  • VOYA Investment Management sold 1,876 Jade Biosciences shares in Q4 2024, an estimated $137K.
  • VOYA Investment Management first reported a position in Jade Biosciences in Q3 2024 and held it in 1 quarter.
  • VOYA Investment Management's Jade Biosciences position peaked at $137K in Q3 2024.
  • 78 funds tracked by Wall St. Rank held Jade Biosciences as of Q4 2024.

Based on VOYA Investment Management's 13F filing for Q4 2024, filed 14 Feb 2025.